These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 26220290)

  • 1. Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China.
    Li J; Yu T; Wang X; Zhou J; Gao R; Zhang F; Gao X; Gao S; Liu X
    Virol J; 2015 Jul; 12():113. PubMed ID: 26220290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
    Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
    Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs.
    Beach NM; Ramamoorthy S; Opriessnig T; Wu SQ; Meng XJ
    Vaccine; 2010 Dec; 29(2):221-32. PubMed ID: 21044670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs.
    Fenaux M; Opriessnig T; Halbur PG; Elvinger F; Meng XJ
    J Virol; 2004 Jun; 78(12):6297-303. PubMed ID: 15163723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated chimeric porcine circovirus (PCV) 1-2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233.
    Li J; Yu T; Zhang F; Wang X; Zhou J; Gao X; Gao S; Liu X
    Arch Virol; 2017 Jan; 162(1):235-246. PubMed ID: 27722993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
    Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
    Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A candidate inactivated chimeric vaccine PCV1-2 constructed based on PCV1 and PCV2 isolates originating in China and its evaluation in conventional pigs in regard to protective efficacy against PCV2 infection.
    Xujie L; Xiaobo W; Yi S; Jing F; Song G; Xiufan L
    Microbiol Immunol; 2011 Apr; 55(4):254-66. PubMed ID: 21244470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efficacious in a PCV2b-PRRSV-PPV challenge model.
    Opriessnig T; Shen HG; Pal N; Ramamoorthy S; Huang YW; Lager KM; Beach NM; Halbur PG; Meng XJ
    Clin Vaccine Immunol; 2011 Aug; 18(8):1261-8. PubMed ID: 21653745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colonisation of mice and pigs by a chimeric porcine circovirus 1-2 prototype vaccine strain and a PCV2 isolate originating in China and their induction of cytokines.
    Cui X; Wang X; Gao Q; Liu X; Kai Y; Chen C; Gao S
    J Virol Methods; 2020 Sep; 283():113905. PubMed ID: 32502500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge.
    Seo HW; Oh Y; Han K; Park C; Chae C
    BMC Vet Res; 2012 Oct; 8():194. PubMed ID: 23078878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with inactivated or live-attenuated chimeric PCV1-2 results in decreased viremia in challenge-exposed pigs and may reduce transmission of PCV2.
    Hemann M; Beach NM; Meng XJ; Halbur PG; Opriessnig T
    Vet Microbiol; 2012 Jul; 158(1-2):180-6. PubMed ID: 22341313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Efficacy and Cross-Protective Immunity of Live-Attenuated Chimeric PCV1-2b Vaccine Against PCV2b and PCV2d Subtype Challenge in Pigs.
    Huan C; Fan M; Cheng Q; Wang X; Gao Q; Wang W; Gao S; Liu X
    Front Microbiol; 2018; 9():455. PubMed ID: 29599761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric virus created by DNA shuffling of the capsid genes of different subtypes of porcine circovirus type 2 (PCV2) in the backbone of the non-pathogenic PCV1 induces protective immunity against the predominant PCV2b and the emerging PCV2d in pigs.
    Matzinger SR; Opriessnig T; Xiao CT; Catanzaro N; Beach NM; Slade DE; Nitzel GP; Meng XJ
    Virology; 2016 Nov; 498():82-93. PubMed ID: 27564544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of antigenic epitopes of porcine reproductive and respiratory syndrome virus (PRRSV) in a modified live-attenuated porcine circovirus type 2 (PCV2) vaccine virus (PCV1-2a) as a potential bivalent vaccine against both PCV2 and PRRSV.
    Piñeyro PE; Kenney SP; Giménez-Lirola LG; Heffron CL; Matzinger SR; Opriessnig T; Meng XJ
    Virus Res; 2015 Dec; 210():154-64. PubMed ID: 26239318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A live-attenuated and an inactivated chimeric porcine circovirus (PCV)1-2 vaccine are both effective at inducing a humoral immune response and reducing PCV2 viremia and intrauterine infection in female swine of breeding age.
    Hemann M; Beach NM; Meng XJ; Wang C; Halbur PG; Opriessnig T
    Can J Vet Res; 2014 Jan; 78(1):8-16. PubMed ID: 24396175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
    Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
    Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2.
    Opriessnig T; Gerber PF; Xiao CT; Halbur PG; Matzinger SR; Meng XJ
    Vaccine; 2014 Jul; 32(34):4342-8. PubMed ID: 24929119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA.
    Shen HG; Halbur PG; Opriessnig T
    J Gen Virol; 2012 Jun; 93(Pt 6):1345-1355. PubMed ID: 22398315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein.
    Guo LJ; Fu YJ; Huang LP; Wang YP; Wei YW; Wu HL; Liu CM
    Vaccine; 2015 Jul; 33(31):3752-7. PubMed ID: 26051516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
    Opriessnig T; Castro AMMG; Karuppanan AK; Gauger PC; Halbur PG; Matzinger SR; Meng XJ
    Vaccine; 2019 Oct; 37(44):6688-6695. PubMed ID: 31537445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.